Cidara Therapeutics

Cidara Therapeutics: The underestimated potential of CD388

birdflustocks

Invested

Community Contributor

Published

11 Jan 25

birdflustocks's Fair Value

US$100.00

35.1% undervalued

13 Jan

US$64.93

462.2%

-0.5%

462.2%

-0.5%

Edit anytime before May 14 2:39 AM. Then post Updates to your followers.

Author's Valuation

US$100.0

35.1% undervalued

birdflustocks's Fair Value

Narrative

Updates0

birdflustocks'sFair Value

US$100.0

35.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

78.92%

Biotech revenue growth rate

7.55%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$97.48m

Earnings '35

26.11x

PE Ratio '35

US$2.55b

Market Cap '35

US$2.55b

Market Cap '35

13.86m

No. shares '35

US$183.63

Share Price '35

US$183.63 Share Price '35

Discounted to 2025 @ 6.26% p.a.

US$100.04

Fair Value '25